TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11911996

Group type: EXPERIMENTAL
Intervention: Ethynil estradiol (EE) 50 microg/day
Number of subjects: 25

Group type: COMPARATOR
Intervention: Pentagastrin 30 microg iv bolus
Number of subjects: 25
Study: 10333820

Group type: EXPERIMENTAL
Intervention: Loperamide-simethicone (2 mg loperamide and 125 mg simethicone)
Number of subjects: 493

Group type: COMPARATOR
Intervention: Loperamide alone (2 mg)
Number of subjects: 493

Group type: COMPARATOR
Intervention: Simethicone alone (125 mg)
Number of subjects: 493

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 493
Study: 12165787

Group type: EXPERIMENTAL
Intervention: Midazolam (0.07 mg/kg)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Diazepam (0.15 mg/kg)
Number of subjects: 71
Study: 1888051

Group type: EXPERIMENTAL
Intervention: Transesophageal Doppler-derived cardiac output (DdCO)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Thermodilution cardiac output (TdCO)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Comparison of DdCO and TdCO
Number of subjects: 33
Study: 6358654

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CyA) alone
Number of subjects: 62

Group type: COMPARATOR
Intervention: Conventional immunosuppression (low-dose steroids)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CyA) with low-dose steroids
Number of subjects: 62
Study: 31930897

Group type: EXPERIMENTAL
Intervention: Acupuncture under hypnosis (first-time)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Acupuncture after wakened-up (second-time)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Acupuncture in clear consciousness (first-time, control group)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Acupuncture after hypnosis (second-time, control group)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Acupuncture after hypnosis (second-time) vs. first-time acupuncture (control group)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Acupuncture under hypnosis (first-time) vs. control group (first-time)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Acupuncture after hypnosis (second-time) vs. control group (second-time)
Number of subjects: 52
Study: 31400624

Group type: EXPERIMENTAL
Intervention: Adjunctive riluzole
Number of subjects: 66
Study: 29530340

Group type: EXPERIMENTAL
Intervention: Topical SR-T100 gel
Number of subjects: 113

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 113
Study: 26174046

Group type: EXPERIMENTAL
Intervention: Educational intervention (handoff skills training workshop)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Real-time handoffs by intervention students
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untrained control students
Number of subjects: 0
Study: 26799887

Group type: EXPERIMENTAL
Intervention: Facebook group adjunct to mHealth physical activity intervention
Number of subjects: 30
Study: 22652361

Group type: EXPERIMENTAL
Intervention: ePHF for 3 months
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: ePHF for 8 months
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: ePHF for 1 month
Number of subjects: 4

Group type: COMPARATOR
Intervention: CMF for 8 months
Number of subjects: 4
Study: 20012296

Group type: EXPERIMENTAL
Intervention: Mechanical bowel preparation (MBP)
Number of subjects: 37

Group type: COMPARATOR
Intervention: No mechanical bowel preparation (Control)
Number of subjects: 37
Study: 18797469

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with uracil-tegafur (UFT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 0
Study: 15833522

Group type: EXPERIMENTAL
Intervention: Co-administration of 7.5 mg intranasal PT-141 and 25 mg sildenafil
Number of subjects: 19

Group type: COMPARATOR
Intervention: 25 mg sildenafil and intranasal placebo spray
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo tablet and intranasal placebo spray
Number of subjects: 19
Study: 11805693

Group type: EXPERIMENTAL
Intervention: Belt (10 mm Hg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Belt (20 mm Hg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: No belt (0 mm Hg)
Number of subjects: 11
Study: 10365639

Group type: EXPERIMENTAL
Intervention: Haloperidol (HAL)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Haloperidol (HAL) at doses less than 0.2 mg/kg
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Haloperidol (HAL) at doses more than 0.2 mg/kg
Number of subjects: 66
Study: 8748428

Group type: EXPERIMENTAL
Intervention: 1 mg of alprazolam twice daily
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 200 mg of nefazodone twice daily
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Combination of 1 mg of alprazolam and 200 mg of nefazodone twice daily
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 2035569

Group type: EXPERIMENTAL
Intervention: Sterile water blocks
Number of subjects: 272

Group type: COMPARATOR
Intervention: Saline solution blocks
Number of subjects: 272
Study: 6138087

Group type: COMPARATOR
Intervention: Midazolam 15 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Midazolam 30 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31913428

Group type: EXPERIMENTAL
Intervention: Oral Janus kinase 1 inhibitor abrocitinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 31359782

Group type: EXPERIMENTAL
Intervention: Biofortified recipes
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control recipes
Number of subjects: 52
Study: 28608261

Group type: EXPERIMENTAL
Intervention: 2.0-mm locking plates
Number of subjects: 87

Group type: COMPARATOR
Intervention: Conventional 2.0- or 2.4-mm plates
Number of subjects: 87
Study: 26689589

Group type: EXPERIMENTAL
Intervention: E2012 (20 or 80 mg/kg)
Number of subjects: 7
Study: 25117805

Group type: EXPERIMENTAL
Intervention: MAINTAIN intervention for 40 weeks, followed by 16 weeks of no intervention contact
Number of subjects: 230

Group type: COMPARATOR
Intervention: Usual care for 56 weeks
Number of subjects: 230
Study: 22003053

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (20 mg single dose)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (20 mg/day for 21 days)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (20 mg/day for 21 days) and Celecoxib (100 mg bid)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (21 days)
Number of subjects: 48
Study: 19916262

Group type: EXPERIMENTAL
Intervention: Low fluence high repetition rate diode laser (5-10 J/cm2, 10 Hz, Soprano XL in SHR mode)
Number of subjects: 25

Group type: COMPARATOR
Intervention: High fluence low repetition rate diode laser (25-40 J/cm2, LightSheer ET)
Number of subjects: 25
Study: 17263737

Group type: EXPERIMENTAL
Intervention: Intranasal clonidine 4 microg/kg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Oral clonidine 4 microg/kg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intranasal clonidine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Oral clonidine
Number of subjects: 40
Study: 17877886

Group type: EXPERIMENTAL
Intervention: Episodic therapy with antiviral medications (1-, 2-, and 3-day courses compared to standard 5-day regimens)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Suppressive antiviral therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antiherpes therapy in HIV-positive patients
Number of subjects: 0
Study: 15376212

Group type: EXPERIMENTAL
Intervention: Respirator
Number of subjects: 22

Group type: COMPARATOR
Intervention: Unprotected
Number of subjects: 22
Study: 10867091

Group type: EXPERIMENTAL
Intervention: Plant stanol ester spread (5.1 g/day)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Placebo spread
Number of subjects: 167
Study: 9772413

Group type: EXPERIMENTAL
Intervention: Captopril (6.25 mg initial dose, 12.5 mg 2 hours later, and then 12.5 mg three times daily for 4 weeks)
Number of subjects: 14962

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14962
Study: 8246027

Group type: EXPERIMENTAL
Intervention: 5-FU plus levamisole
Number of subjects: 1025

Group type: COMPARATOR
Intervention: Levamisole alone
Number of subjects: 1025

Group type: COMPARATOR
Intervention: Observation only (untreated controls)
Number of subjects: 1025
Study: 3698180

Group type: EXPERIMENTAL
Intervention: High-dose IV metoclopramide
Number of subjects: 78

Group type: COMPARATOR
Intervention: High-dose IV dexamethasone
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: High-dose IV metoclopramide (HD-CDDP group)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: High-dose IV metoclopramide (LD-CDDP group)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: High-dose IV metoclopramide (LD-CDDP combination chemotherapy)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: High-dose IV metoclopramide (previously untreated patients)
Number of subjects: 78

Group type: COMPARATOR
Intervention: High-dose IV dexamethasone (LD-CDDP monochemotherapy)
Number of subjects: 78
Study: 31450983

Group type: EXPERIMENTAL
Intervention: Luseogliflozin-sitagliptin (LS); luseogliflozin 2.5 mg for 0-12 weeks, then luseogliflozin plus sitagliptin 50 mg for 12-24 weeks
Number of subjects: 41

Group type: COMPARATOR
Intervention: Sitagliptin-luseogliflozin (SL); sitagliptin 50 mg for 0-12 weeks, then sitagliptin plus luseogliflozin 2.5 mg for 12-24 weeks
Number of subjects: 41
Study: 28629472

Group type: EXPERIMENTAL
Intervention: S100 measured at 24 hours after OHCA
Number of subjects: 687

Group type: EXPERIMENTAL
Intervention: S100 measured at 48 hours after OHCA
Number of subjects: 687

Group type: EXPERIMENTAL
Intervention: S100 measured at 72 hours after OHCA
Number of subjects: 687

Group type: EXPERIMENTAL
Intervention: S100 levels at 24 hours in 33 °C group
Number of subjects: 687

Group type: EXPERIMENTAL
Intervention: S100 levels at 72 hours in 33 °C group
Number of subjects: 687

Group type: EXPERIMENTAL
Intervention: S100 added to prognostication model including baseline variables and target temperature
Number of subjects: 687

Group type: EXPERIMENTAL
Intervention: S100 in multivariable analyses
Number of subjects: 687

Group type: EXPERIMENTAL
Intervention: S100 added to model including neuron-specific enolase (NSE)
Number of subjects: 687
Study: 27391598

Group type: EXPERIMENTAL
Intervention: Eribulin mesylate (1.4 mg/m² on days 1 and 8 every 21 days)
Number of subjects: 1864

Group type: COMPARATOR
Intervention: Capecitabine (1.25 g/m² twice daily on days 1-14 every 21 days)
Number of subjects: 1864

Group type: COMPARATOR
Intervention: Treatment of physician's choice
Number of subjects: 1864

Group type: EXPERIMENTAL
Intervention: Eribulin (as above)
Number of subjects: 1864

Group type: COMPARATOR
Intervention: Capecitabine (as above)
Number of subjects: 1864
Study: 23098678

Group type: EXPERIMENTAL
Intervention: Tramadol (200 mg and 400 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Oxycodone (20 mg and 40 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Codeine (100 mg and 200 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 21725510

Group type: EXPERIMENTAL
Intervention: Intermittent sustained-release sodium-fluoride (50 mg) with colecalciferol (1000 IU) and calcium-citrate (800 mg)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Intravenous ibandronate (1 mg/3-monthly)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Sodium-fluoride
Number of subjects: 66
Study: 19515090

Group type: EXPERIMENTAL
Intervention: Computer-assisted dosing
Number of subjects: 13219

Group type: COMPARATOR
Intervention: Manual dosing
Number of subjects: 13219
Study: 16995870

Group type: EXPERIMENTAL
Intervention: Grapefruit juice
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sun Drop
Number of subjects: 12

Group type: COMPARATOR
Intervention: Fresca
Number of subjects: 12

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 12
Study: 15186867

Group type: EXPERIMENTAL
Intervention: Group-based counselling programme
Number of subjects: 63
Study: 11422129

Group type: EXPERIMENTAL
Intervention: House dust mite (HDM) extract
Number of subjects: 20

Group type: COMPARATOR
Intervention: Isolated major allergens (Der p 1 and Der p 2)
Number of subjects: 20
Study: 10193286

Group type: EXPERIMENTAL
Intervention: Tramadol 3 mg kg-1
Number of subjects: 40

Group type: COMPARATOR
Intervention: Morphine 0.2 mg kg-1
Number of subjects: 40
Study: 8092425

Group type: EXPERIMENTAL
Intervention: sublingual therapy with a solution of purified, standardized allergen preparation (Stallergènes)
Number of subjects: 58

Group type: COMPARATOR
Intervention: matched placebo
Number of subjects: 58
Study: 3276185

Group type: EXPERIMENTAL
Intervention: Max-EPA (omega-3 PUFAs, 3.2 g eicosapentaenoic acid and 2.2 g docosahexaenoic acid daily)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Max-EPA (omega-3 PUFAs)
Number of subjects: 8
Study: 31372823

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) treatment for 4 weeks
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: CPAP treatment for 4 weeks (per-protocol analysis)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (observation)
Number of subjects: 90
Study: 30189281

Group type: EXPERIMENTAL
Intervention: Bilateral lateral rectus recession (BLRc)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Unilateral lateral rectus recession combined with medial rectus resection (R&R)
Number of subjects: 197
Study: 28477228

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (300 µg) with intravenous patient-controlled analgesia (IV-PCA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intravenous patient-controlled analgesia (IV-PCA) only
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 26439700

Group type: EXPERIMENTAL
Intervention: S-1 plus cisplatin (CS group)
Number of subjects: 236

Group type: COMPARATOR
Intervention: 5-FU plus cisplatin (CF group)
Number of subjects: 236
Study: 23062958

Group type: EXPERIMENTAL
Intervention: Miniscrews with septum width ≤3 mm
Number of subjects: 40

Group type: COMPARATOR
Intervention: Miniscrews with septum width >3 mm
Number of subjects: 40
Study: 21718543

Group type: EXPERIMENTAL
Intervention: Family-based screen time intervention
Number of subjects: 270

Group type: COMPARATOR
Intervention: Control (no change)
Number of subjects: 270
Study: 18652321

Group type: EXPERIMENTAL
Intervention: Acupuncture with reinforcing and reducing manipulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine western medicine without acupuncture (Control)
Number of subjects: 0
Study: 16863518

Group type: EXPERIMENTAL
Intervention: Systemic Glucantime (20 mg pentavalent antimony/kg/day) plus pentoxifylline (400 mg three times daily) for 20 days
Number of subjects: 64

Group type: COMPARATOR
Intervention: Glucantime (20 mg pentavalent antimony/kg/day) plus placebo (three tablets daily) for 20 days
Number of subjects: 64
Study: 15114430

Group type: EXPERIMENTAL
Intervention: Mometasone furoate aqueous nasal spray (MFANS) 50 microg/spray, 8 sprays per nostril every 8 h for 4 days
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (FPANS) 50 microg/spray, 8 sprays per nostril every 8 h for 4 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo aqueous nasal spray (placebo ANS)
Number of subjects: 12
Study: 11006179

Group type: EXPERIMENTAL
Intervention: Vaginal ring (1g natural progesterone, continuous release for 90 days)
Number of subjects: 658

Group type: COMPARATOR
Intervention: Intramuscular (i.m.) progesterone (50 mg/day for IVF; 100 mg/day for oocyte donation)
Number of subjects: 658

Group type: EXPERIMENTAL
Intervention: Vaginal ring
Number of subjects: 658

Group type: COMPARATOR
Intervention: Intramuscular (i.m.) progesterone
Number of subjects: 658
Study: 9438604

Group type: EXPERIMENTAL
Intervention: Radiotherapy (40 Gy with 5-fluorouracil as a sensitising agent)
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: 6 months chemotherapy (5-fluorouracil and folinic acid)
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Combination of radiotherapy and chemotherapy
Number of subjects: 348

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 348
Study: 3537828

Group type: EXPERIMENTAL
Intervention: Cavinton
Number of subjects: 57

Group type: COMPARATOR
Intervention: Aminophylline
Number of subjects: 57
Study: 29751849

Group type: EXPERIMENTAL
Intervention: Continuous compression stimulation (5-minute massage therapy)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sham massage therapy (touch without compression)
Number of subjects: 32
Study: 26806174

Group type: EXPERIMENTAL
Intervention: Active compression-decompression CPR with CardioPump
Number of subjects: 181

Group type: COMPARATOR
Intervention: Standard CPR
Number of subjects: 181
Study: 25896113

Group type: EXPERIMENTAL
Intervention: BCG immunisation
Number of subjects: 4184

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 4184
Study: 23098698

Group type: EXPERIMENTAL
Intervention: Topical nutmeg extracts (NEMM; mace oil [2%], nutmeg oil [14%], methyl salicylate [6%], menthol [6%], and coconut oil)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo (MM; methyl salicylate [6%], menthol [6%], coconut oil, and alcohol)
Number of subjects: 74
Study: 21072735

Group type: EXPERIMENTAL
Intervention: Diet and exercise training (DET)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Hypocaloric diet (D)
Number of subjects: 33
Study: 18708482

Group type: EXPERIMENTAL
Intervention: Brief intervention using the Drink-less package by a trained registered nurse
Number of subjects: 133

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 133
Study: 17003712

Group type: EXPERIMENTAL
Intervention: Olfactory function improvement (self-assessed as 'better')
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Olfactory function unchanged (self-assessed as 'unchanged')
Number of subjects: 83

Group type: COMPARATOR
Intervention: Olfactory function deterioration (self-assessed as 'worse')
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Increase in TDI score
Number of subjects: 83
Study: 14551526

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft surgery (CABG)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Medical therapy (including statins, ACE inhibitors, thienopyridines, aspirin, beta-blockers)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Revascularization (CABG or PCI)
Number of subjects: 100
Study: 10975752

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (10 mg/kg/day) for 12 months after interferon therapy
Number of subjects: 203

Group type: COMPARATOR
Intervention: Placebo for 12 months after interferon therapy
Number of subjects: 203
Study: 9273082

Group type: EXPERIMENTAL
Intervention: Individual screening by serum PSA assay
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diagnostic examinations (biopsy) and curative treatments (surgery or radiotherapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Screening recommendations
Number of subjects: 0
Study: 8287314

Group type: EXPERIMENTAL
Intervention: Pamidronate disodium 75 mg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Pamidronate disodium 150 mg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Pamidronate disodium 300 mg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Repeated peroral doses of pamidronate disodium (75 and 150 mg) for 10 consecutive days
Number of subjects: 21

Group type: COMPARATOR
Intervention: i.v. infusion of pamidronate disodium 15 mg
Number of subjects: 21
Study: 2953116

Group type: EXPERIMENTAL
Intervention: Hexoprenalin 0.3 microgram/min
Number of subjects: 0

Group type: COMPARATOR
Intervention: Celiprolol (3 X 100 micrograms oral)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29433963

Group type: EXPERIMENTAL
Intervention: Trastuzumab and pertuzumab plus metronomic oral cyclophosphamide
Number of subjects: 80

Group type: COMPARATOR
Intervention: Trastuzumab and pertuzumab
Number of subjects: 80
Study: 28947345

Group type: EXPERIMENTAL
Intervention: AMA1‐DiCo with Alhydrogel®
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: AMA1‐DiCo with GLA‐SE
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: AMA1‐DiCo/GLA‐SE
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 25762809

Group type: EXPERIMENTAL
Intervention: Active video game play (Kinect Adventures on Xbox 360)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Resting control
Number of subjects: 26

Group type: COMPARATOR
Intervention: Seated video game play (Xbox 360)
Number of subjects: 26
Study: 24113579

Group type: EXPERIMENTAL
Intervention: Aggressive video
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control video
Number of subjects: 0
Study: 19763690

Group type: EXPERIMENTAL
Intervention: Umbrella technique of mesh insertion
Number of subjects: 30

Group type: COMPARATOR
Intervention: Roll-up technique of mesh insertion
Number of subjects: 30
Study: 18398153

Group type: EXPERIMENTAL
Intervention: Bexarotene 400 mg/m(2)/d combined with carboplatin and paclitaxel
Number of subjects: 612

Group type: COMPARATOR
Intervention: Carboplatin and paclitaxel alone
Number of subjects: 612
Study: 16840727

Group type: EXPERIMENTAL
Intervention: 30 mg once-daily lenalidomide
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 15 mg twice-daily lenalidomide
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Dexamethasone (added in 68 patients)
Number of subjects: 70
Study: 12741933

Group type: EXPERIMENTAL
Intervention: 1 mg dexamethasone in 1 mL saline through one subcutaneous site (test site)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control site (1 mL saline without dexamethasone)
Number of subjects: 38
Study: 12840636

Group type: EXPERIMENTAL
Intervention: F(I)O(2) 0.26 (P(I)O(2) approximately 159 Torr)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: F(I)O(2) 0.60 (P(I)O(2) approximately 366 Torr)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control trial (F(I)O(2) 0.21, P(I)O(2) approximately 128 Torr)
Number of subjects: 19
Study: 10599357

Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg/day)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 7573744

Group type: EXPERIMENTAL
Intervention: CUSUM analysis of postoperative SCCAg levels
Number of subjects: 75
Study: 1672967

Group type: EXPERIMENTAL
Intervention: Captopril 50 mg twice daily
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 6130595

Group type: EXPERIMENTAL
Intervention: oxprenolol (n = 10)
Number of subjects: 19

Group type: COMPARATOR
Intervention: atenolol (n = 9)
Number of subjects: 19